ArticleGenes & diseases2015
MicroRNAs: Role in Hepatitis C Virus pathogenesis.
Article in Genes & diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 85 citations in OpenAlex.
- Longitudinal Follow-Up of microRNA Expression During Hepatitis E Virus Infection in Immunocompromised Hosts.Biomolecules · 2026Article
- Serum-Based miRNA Panel as Diagnostic Biomarkers for Hepatitis C Virus-Induced Hepatocellular Carcinoma: A Cross-Sectional Study.Health science reports · 2026Article
- Epigenetic Mechanisms Involved in Hcv Infection and Human HCC.International journal of molecular sciences · 2025Review
- Differential miRNA signatures in Hepatitis E Virus Infection: Insights into acute, chronic, and pregnancy-related outcomes.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Review
- Micro RNAs as a potential biomarker for predicting liver fibrosis severity in hepatitis C virus affected patients.World journal of virology · 2025Article
- Extracellular vesicles derived microRNAs as non-invasive markers of liver fibrosis in chronically infected HCV patients: a pilot study.Non-coding RNA research · 2025Article
- A comprehensive overview on the crosstalk between microRNAs and viral pathogenesis and infection.Medicinal research reviews · 2025Review
- From discovery to treatment: tracing the path of hepatitis E virus.Virology journal · 2024Review
- Expression of miRNAs (146a and 155) in human peri-implant tissue affected by peri-implantitis: a case control study.BMC oral health · 2024Article
- Cross Talk between MicroRNAs and Dengue Virus.The American journal of tropical medicine and hygiene · 2024Review
- Potential role of microRNAs in personalized medicine against hepatitis: a futuristic approach.Archives of virology · 2024Review
- Data report on gene expression after hepatic portal vein ligation (PVL) in rats.Frontiers in genetics · 2024Article
- HCV and HCC Tango-Deciphering the Intricate Dance of Disease: A Review Article.International journal of molecular sciences · 2023Review
- MicroRNA signature from extracellular vesicles of HCV/HIV co-infected individuals differs from HCV mono-infected.Journal of molecular medicine (Berlin, Germany) · 2023Article
- Specific Plasma MicroRNA Signatures Underlying the Clinical Outcomes of Hepatitis E Virus Infection.Microbiology spectrum · 2023Article
- Serum MicroRNAs as Predictors for HCV Progression and Response to Treatment in Pakistani Patients.Genes · 2023Article
- Article
- Micro RNAs-The Small Big Players in Hepatitis E Virus Infection: A Comprehensive Review.Biomolecules · 2022Review
- microRNA-27b regulates hepatic lipase enzyme LIPC and reduces triglyceride degradation during hepatitis C virus infection.The Journal of biological chemistry · 2022Article
- MicroRNA let-7b inhibits hepatitis C virus and induces apoptosis in human hepatoma cells.Molecular biology reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Hepatitis C virus (HCV) is a global health burden with an estimated 170-200 million peoples chronically infected worldwide. HCV infection remains as an independent risk factor for chronic hepatitis, liver cirrhosis, hepatocellular carcinoma, and a major reason for liver transplantation. Discovery of direct acting antiviral (DAA) drugs have shown promising results with more than 90% success rate in clearing the HCV RNA in patients, although long-term consequences remain to be evaluated. microRNAs (miRNAs) are important players in establishment of HCV infection and target crucial host cellular factors needed for productive HCV replication and augmented cell growth. Altered expression of miRNAs is involved in the pathogenesis associated with HCV infection by controlling signaling pathways such as immune response, proliferation and apoptosis. miRNA is emerging as a means of communication between various cell types inside the liver. There is likely possibility of developing circulating miRNAs as biomarkers of disease progression and can also serve as diagnostic tool with potential of early therapeutic intervention in HCV associated end stage liver disease. This review focuses on recent studies highlighting the contribution of miRNAs in HCV life cycle and their coordinated regulation in HCV mediated liver disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.